首页|奥曲肽及乌司他丁联合治疗重症急性胰腺炎的疗效及对肠道功能的影响

奥曲肽及乌司他丁联合治疗重症急性胰腺炎的疗效及对肠道功能的影响

扫码查看
目的 研讨奥曲肽联合乌司他丁治疗重症急性胰腺炎(severe acute pancreatitis,SAP)的疗效及对肠道功能的影响.方法 随机选取2021年4月—2023年9月福建省南平市第一医院收治的70例SAP患者为研究对象,根据不同治疗方法分为对照组和观察组,各35例.对照组予以奥曲肽治疗,观察组予以奥曲肽联合乌司他丁治疗,对比两组的疗效、症状控制时间、炎性因子以及肠道功能.结果 观察组治疗有效率为94.29%(33/35),高于对照组的77.14%(27/35),差异有统计学意义(χ2=4.200;P=0.040).观察组胰腺炎症状(腹痛、腹胀及恶心呕吐)控制时间均短于对照组,差异均有统计学意义(P均<0.05).治疗后,观察组C反应蛋白(C-reactive protein,CRP)、降钙素原(procalcitonin,PCT)和白细胞计数(white blood cell count,WBC)水平均低于对照组,差异均有统计学意义(P均<0.05).治疗后,观察组肠鸣音恢复时间、肛门恢复排气时间、肛门恢复排便时间均短于对照组,差异均有统计学意义(P均<0.05).结论 奥曲肽联合乌司他丁治疗SAP可提升疗效,加快胰腺炎症状缓解,减轻机体炎性反应,促进患者肠道功能恢复.
Efficacy of Octreotide Combined with Ulinastatin on Curative Effect and Intestinal Function in Patients with Severe Acute Pancreatitis
Objective To investigate the efficacy of octreotide combined with ulinastatin in the treatment of severe acute pancreatitis(SAP)and its effect on intestinal function.Methods A total of 70 SAP patients admitted to Nanping First Hospital of Fujian Province from April 2021 to September 2023 were randomly selected as the research objects.According to different treatment methods,they were divided into control group and observation group,with 35 cases in each group.The control group was treated with octreotide,and the observation group was treated with octreotide com-bined with ulinastatin.The efficacy,symptom control time,inflammatory factors and intestinal function of the two groups were compared.Results The effective rate of treatment in the observation group was 94.29%(33/35),which was higher than 77.14%(27/35)in the control group,and the difference was statistically significant(χ2=4.200;P=0.040).The control time of pancreatitis symptoms(abdominal pain,abdominal distension,nausea and vomiting)in the observation group were shorter than those in the control group,and the differences were statistically significant(all P<0.05).After treatment,the levels of C-reactive protein(CRP),procalcitonin(PCT)and white blood cell count(WBC)in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).After treatment,the recovery time of bowel sounds,the recovery time of anus exhaust and the recovery time of anus defecation in the observation group were shorter than those in the control group,and the differences were statistically significant(all P<0.05).Conclusion Octreotide combined with ulinastatin in the treatment of SAP can im-prove the curative effect,accelerate the relief of pancreatitis symptoms,reduce the body's inflammatory response,and promote the recovery of intestinal function.

Severe acute pancreatitisOctreotideUlinastatinIntestinal functionInflammatory factor

陆信顺、詹雪芳、张荣娟

展开 >

福建省南平市第一医院消化内科,福建 南平 353000

福建省南平市第一医院血液净化中心,福建 南平 353000

重症急性胰腺炎 奥曲肽 乌司他丁 肠道功能 炎性因子

2024

中外医疗
卫生部医院管理研究所 二十一世纪联合创新医药科学研究院

中外医疗

影响因子:0.909
ISSN:1674-0742
年,卷(期):2024.43(34)